{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T20:29:42Z","timestamp":1779136182340,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T00:00:00Z","timestamp":1625270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T00:00:00Z","timestamp":1625270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Hematol Blood Transfus"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s12288-021-01466-1","type":"journal-article","created":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T10:02:47Z","timestamp":1625306567000},"page":"282-289","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Secondary Hypogammaglobulinemia in Patients with Chronic Lymphocytic Leukemia Receiving Ibrutinib Therapy"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1052-9800","authenticated-orcid":false,"given":"Serhat","family":"\u00c7elik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leylag\u00fcl","family":"Kaynar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeynep Tu\u011fba","family":"G\u00fcven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Baydar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muzaffer","family":"Keklik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"\u00c7etin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"\u00dcnal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatih","family":"Demirkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,3]]},"reference":[{"issue":"25","key":"1466_CR1","first-page":"2745","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H et al (2018) iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood J Am Soc Hematol 131(25):2745\u20132760","journal-title":"Blood J Am Soc Hematol"},{"issue":"1","key":"1466_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/bmb\/ldn034","volume":"87","author":"A Hamblin","year":"2008","unstructured":"Hamblin A, Hamblin T (2008) The immunodeficiency of chronic lymphocytic leukaemia. Br Med Bull 87(1):49\u201362","journal-title":"Br Med Bull"},{"issue":"3","key":"1466_CR3","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10875-014-9995-5","volume":"34","author":"F Dhalla","year":"2014","unstructured":"Dhalla F, Lucas M, Schuh A, Bhole M, Jain R, Patel SY et al (2014) Antibody deficiency secondary to chronic lymphocytic leukemia: should patients be treated with prophylactic replacement immunoglobulin? J Clin Immunol 34(3):277\u2013282","journal-title":"J Clin Immunol"},{"key":"1466_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.leukres.2017.02.011","volume":"57","author":"FR Mauro","year":"2017","unstructured":"Mauro FR, Morabito F, Vincelli ID, Petrucci L, Campanelli M, Salaroli A et al (2017) Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia. Leuk Res 57:65\u201371","journal-title":"Leuk Res"},{"issue":"1","key":"1466_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3109\/10428194.2012.706285","volume":"54","author":"JA Freeman","year":"2013","unstructured":"Freeman JA, Crassini KR, Best OG, Forsyth CJ, Mackinlay NJ, Han P et al (2013) Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia. Leuk Lymphoma 54(1):99\u2013104","journal-title":"Leuk Lymphoma"},{"issue":"17","key":"1466_CR6","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1002\/cncr.29438","volume":"121","author":"SA Parikh","year":"2015","unstructured":"Parikh SA, Leis JF, Chaffee KG, Call TG, Hanson CA, Ding W et al (2015) Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: natural history, clinical correlates, and outcomes. Cancer 121(17):2883\u20132891","journal-title":"Cancer"},{"issue":"1","key":"1466_CR7","first-page":"58","volume":"2","author":"Z Pan","year":"2007","unstructured":"Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC et al (2007) Discovery of selective irreversible inhibitors for Bruton\u2019s tyrosine kinase. ChemMedChem Chem Enabl Drug Discov 2(1):58\u201361","journal-title":"ChemMedChem Chem Enabl Drug Discov"},{"key":"1466_CR8","unstructured":"Network NCC. Chronic lymphocytic leukemia, small lymphocytic leukemia 2019, December 20. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cll.pdf"},{"issue":"5","key":"1466_CR9","doi-asserted-by":"publisher","first-page":"v78","DOI":"10.1093\/annonc\/mdv303","volume":"26","author":"B Eichhorst","year":"2015","unstructured":"Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M et al (2015) Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(5):v78\u2013v84","journal-title":"Ann Oncol"},{"issue":"6","key":"1466_CR10","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6):649\u2013656","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"1466_CR11","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/j.1532-5415.1995.tb06377.x","volume":"43","author":"PA Parmelee","year":"1995","unstructured":"Parmelee PA, Thuras PD, Katz IR, Lawton MP (1995) Validation of the cumulative illness rating scale in a geriatric residential population. J Am Geriatr Soc 43(2):130\u2013137","journal-title":"J Am Geriatr Soc"},{"issue":"19","key":"1466_CR12","first-page":"2213","volume":"126","author":"C Sun","year":"2015","unstructured":"Sun C, Tian X, Lee YS, Gunti S, Lipsky A, Herman SE et al (2015) Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood J Am Soc Hematol 126(19):2213\u20132219","journal-title":"Blood J Am Soc Hematol"},{"issue":"1","key":"1466_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/ejh.12290","volume":"93","author":"L Shvidel","year":"2014","unstructured":"Shvidel L, Tadmor T, Braester A, Bairey O, Rahimi-Levene N, Herishanu Y et al (2014) Serum immunoglobulin levels at diagnosis have no prognostic significance in stage A chronic lymphocytic leukemia: a study of 1113 cases from the Israeli CLL Study Group. Eur J Haematol 93(1):29\u201333","journal-title":"Eur J Haematol"},{"issue":"1","key":"1466_CR14","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/ajcp\/87.1.60","volume":"87","author":"FR Davey","year":"1987","unstructured":"Davey FR, Kurec AS, Tomar RH, Smith JR (1987) Serum immunoglobulins and lymphocyte subsets in chronic lymphocytic leukemia. Am J Clin Pathol 87(1):60\u201365","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"1466_CR15","first-page":"279","volume":"61","author":"C Rozman","year":"1988","unstructured":"Rozman C, Montserrat E, Vi\u00f1olas N (1988) Serum immunoglobulins in B-chronic lymphocytic leukemia. Nat Hist Prognost Sig Cancer 61(2):279\u2013283","journal-title":"Nat Hist Prognost Sig Cancer"},{"issue":"3","key":"1466_CR16","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/j.1365-2249.1992.tb06965.x","volume":"89","author":"H Griffiths","year":"1992","unstructured":"Griffiths H, Lea J, Bunch C, Lee M, Chapel H (1992) Predictors of infection in chronic lymphocytic leukaemia (CLL). Clin Exp Immunol 89(3):374\u2013377","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"1466_CR17","doi-asserted-by":"publisher","first-page":"e26914","DOI":"10.1002\/pbc.26914","volume":"65","author":"A Doan","year":"2018","unstructured":"Doan A, Pulsipher MA (2018) Hypogammaglobulinemia due to CAR T-cell therapy. Pediatric Blood Cancer 65(4):e26914","journal-title":"Pediatric Blood Cancer"},{"issue":"1","key":"1466_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA et al (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369(1):32\u201342","journal-title":"N Engl J Med"},{"issue":"12","key":"1466_CR19","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1080\/10428194.2019.1620944","volume":"60","author":"M Dimou","year":"2019","unstructured":"Dimou M, Iliakis T, Pardalis V, Bitsani C, Vassilakopoulos TP, Angelopoulou M et al (2019) Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece. Leuk Lymphoma 60(12):2939\u20132945","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"1466_CR20","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.3324\/haematol.2016.144576","volume":"101","author":"M Winqvist","year":"2016","unstructured":"Winqvist M, Asklid A, Andersson P-O, Karlsson K, Karlsson C, Lauri B et al (2016) Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group. Haematologica 101(12):1573\u20131580","journal-title":"Haematologica"},{"issue":"8","key":"1466_CR21","doi-asserted-by":"publisher","first-page":"E166","DOI":"10.1002\/ajh.24773","volume":"92","author":"L Ysebaert","year":"2017","unstructured":"Ysebaert L, Aurran-Schleinitz T, Dartigeas C, Dilhuydy MS, Feugier P, Michallet AS et al (2017) Real-world results of ibrutinib in relapsed\/refractory CLL in France: early results on a large series of 428 patients. Am J Hematol 92(8):E166","journal-title":"Am J Hematol"},{"issue":"1","key":"1466_CR22","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","volume":"15","author":"S O'Brien","year":"2014","unstructured":"O\u2019Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA et al (2014) Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b\/2 trial. Lancet Oncol 15(1):48\u201358","journal-title":"Lancet Oncol"},{"issue":"9","key":"1466_CR23","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1080\/1744666X.2016.1208085","volume":"12","author":"C Agostini","year":"2016","unstructured":"Agostini C, Blau I-W, Kimby E, Plesner T (2016) Prophylactic immunoglobulin therapy in secondary immune deficiency\u2014an expert opinion. Expert Rev Clin Immunol 12(9):921\u2013926","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"1466_CR24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3747\/co.23.2810","volume":"23","author":"S Lachance","year":"2016","unstructured":"Lachance S, Christofides A, Lee J, Sehn L, Ritchie B, Shustik C et al (2016) A Canadian perspective on the use of immunoglobulin therapy to reduce infectious complications in chronic lymphocytic leukemia. Curr Oncol 23(1):42","journal-title":"Curr Oncol"},{"key":"1466_CR25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1365-2249.2011.04387.x","volume":"164","author":"S Kaveri","year":"2011","unstructured":"Kaveri S, Maddur M, Hegde P, Lacroix-Desmazes S, Bayry J (2011) Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clin Exp Immunol 164:2\u20135","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"1466_CR26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1365-2257.1995.tb00322.x","volume":"17","author":"B Boughton","year":"1995","unstructured":"Boughton B, Jackson N, Lim S, Smith N (1995) Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia. Clin Lab Haematol 17(1):75\u201380","journal-title":"Clin Lab Haematol"},{"issue":"1","key":"1466_CR27","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1365-2141.1994.tb05002.x","volume":"88","author":"H Chapel","year":"1994","unstructured":"Chapel H, Dicato M, Gamm H, Brennan V, Ries F, Bunch C et al (1994) Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes. Br J Haematol 88(1):209\u2013212","journal-title":"Br J Haematol"},{"issue":"5","key":"1466_CR28","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1093\/rheumatology\/ker417","volume":"51","author":"I De La Torre","year":"2012","unstructured":"De La Torre I, Leandro MJ, Valor L, Becerra E, Edwards JC, Cambridge G (2012) Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics. Rheumatology 51(5):833\u2013840","journal-title":"Rheumatology"},{"issue":"3\u20134","key":"1466_CR29","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3109\/10428199909050963","volume":"34","author":"J Aittoniemi","year":"1999","unstructured":"Aittoniemi J, Miettinen A, Lainf S, Sinisalo M, Laippala P, Vilpo L et al (1999) Opsonising immunoglobulins and mannan-binding lectin in chronic lymphocytic leukemia. Leuk Lymphoma 34(3\u20134):381\u2013385","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"1466_CR30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3109\/00365548.2013.840920","volume":"46","author":"M Fabbiani","year":"2014","unstructured":"Fabbiani M, Mondi A, Colafigli M, D\u2019Ettorre G, Paoletti F, D\u2019Avino A et al (2014) Safety and efficacy of treatment switch to raltegravir plus tenofovir\/emtricitabine or abacavir\/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study). Scand J Infect Dis 46(1):34\u201345","journal-title":"Scand J Infect Dis"}],"container-title":["Indian Journal of Hematology and Blood Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-021-01466-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12288-021-01466-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-021-01466-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T02:06:52Z","timestamp":1649729212000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12288-021-01466-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,3]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1466"],"URL":"https:\/\/doi.org\/10.1007\/s12288-021-01466-1","relation":{},"ISSN":["0971-4502","0974-0449"],"issn-type":[{"value":"0971-4502","type":"print"},{"value":"0974-0449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,3]]},"assertion":[{"value":"3 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}